Claus Andersson Email and Phone Number
Claus Andersson's Location
Copenhagen, Capital Region of Denmark, Denmark, Denmark
Claus Andersson's Contact Details
Claus Andersson work email
- Valid
- Valid
Claus Andersson personal email
n/a
Claus Andersson phone numbers
About Claus Andersson
General Partner at Sunstone Life Science Ventures where I started in 2005. I draw from 25+ years of experience in venture capital and from founding and co-founding 4 companies with some years in corporate R&D.I support founders, entrepreneurs, and scientists who are developing novel solutions for unmet medical needs, especially in the field of metabolic disorders, cardiology, and oncology. Building on experience from life science venture capital, drug development, and biotech board leadership to identify, evaluate, and invest in promising companies, and to guide them through strategic direction, financing strategies, IPOs and M&As.Engaging as an active board member in biotech companies that are advancing regenerative treatments for heart failure, cancer, obesity, diabetes, and non-coding RNA therapies. I have closed deals for over 22 private and public companies in the portfolio, managing assets of +500 MEUR.
Claus Andersson's Current Company Details
Claus Andersson Work Experience Details
-
General PartnerSunstone Life Science Ventures Apr 2005 - PresentCopenhagen, Capital Region, DkSunstone - Life Science VenturesInvesting in development of prescription drugs based on new chemical entities and active pharmaceutical ingredients that work according to a well described and evidenced biological/molecular mechanism of action. Working with founders, management, co-investors and advisors to develop our portfolio companies to become valuable and interesting targets for acquirers or public stock markets. Total life science funds managed in excess of 500 m€.
-
Member Of The Board Of DirectorsResalis Therapeutics Jan 2024 - PresentTurin, Piedmont, ItResalis Therapeutics’ is based on its unique scientific understanding of the non-coding RNA drug modality and a new biological mechanism of action that enables a therapy for obese that preserves muscle mass to provide a sustainable and durable weight loss effect. The company is starting clinical trials in obese patients in 2024.Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders. -
Member Of The Board Of DirectorsDiogenx Oct 2023 - PresentMarseille, FrDiogenX is a preclinical stage biotech company committed to discover and develop innovative biologics as new therapeutics options for millions of diabetic patients around the world. Focus is on developing a first-in-class regenerative treatment for type 1 diabetes to normalize the lives of patients. -
Member Of The Board Of DirectorsRewind Therapeutics Jan 2023 - PresentHeverlee, Flemish Region, BeRewind is an early-stage biotech company developing a poential therapy for Multiple Sclerosis. Rewind is focused on restoring and protecting the myelin sheet around the nerves in the brain. Loss of myelin can occur for various reasons, e.g., aging, in response to altered neuronal activity, brain injury or disease. The CNS contains a population of stem cells that, under the appropriate conditions and signals, migrate throughout the CNS, differentiate into oligodendrocytes and wrap around neurons to repair the myelin sheath. In this highly regulated way, the CNS has the capacity to remodel and repair itself. -
Member Of The Board Of DirectorsCardior Pharmaceuticals Aug 2021 - May 2024Hanover, Lower Saxony, DeCardior was acquired by Novo Nordisk on May 2nd, 2024. Cardiac dysfunction remains the leading cause of death world-wide, and heart diseases represent a global and increasing burden with prevalence and mortality rates far exceeding those of other diseases. Cardior is based on substantial academic research and proprietary preclinical work in exactly this indication area, and combines new molecular modalities with clinical experience to develop therapies to address heart failure and other cardiovascular diseases. The company has started phase II trials and the first clinical responses quantifying the efficacy of CDR-132L in heart failure patients will be available by 2024. -
Professional Standards, Investeurope (Association Of Venture Capital And Private Equity)Invest Europe Jan 2021 - Dec 2023Brussels, BeContribution of input to the editorial process of sections in the Invest Europe Handbook of Professional Standards (https://www.investeurope.eu/industry-standards/professional-standards) providing a practical guidance on the principles of governance, transparency and accountability and focusing on the relationship between fund managers and their investors, and between managers and the companies they invest in. -
Member Of The Board Of DirectorsIo Biotech Dec 2016 - Jun 2022Copenhagen, Denmark, DkIO Biotech Inc. is a clinical stage biotech company developing disruptive immune therapies i.e. therapeutic cancer vaccines. The company is in Phase 3 pivotal studies in melanoma with outstanding results, and we have listed the company on NASDAQ New York. It is therefore time to leave this board to spend time on new exciting investments. -
Member Of The Board Of DirectorsForendo Pharma Ltd Jul 2019 - Dec 2021Forendo was acquired by Organon in 2021. Forendo Pharma is a clinical stage drug development company, with core competencies in tissue specific hormone mechanisms and therapeutic focus in women’s health. World leading innovator in the endometriosis field, with two active programs. The company was acquired by Organon in December 2021.
-
Member Of The Board Of DirectorsCantargia Ab Jun 2013 - May 2021Lund, Skåne County, SeCantargia AB is listed on NASDAQ main market in Stockholm. The company develops new pharmaceutical treatments against cancers based on anti-body molecules and has particular focus on the target IL1RAP. -
Member Of The Board Of DirectorsAcarix Nov 2011 - May 2020Malmö, Skane County, SeAcarix has developed and commercialized the CADScor® System which combines world class acoustic knowledge and advanced algorithms into a new method for non-invasively obtaining the patient specific CADScore (Coronary Artery Disease Score) in less than 8 minutes. Doctors and specialists use the CADScore to estimate the risk of having occlusions in the arteries of the heart. -
Member Of The Board Of DirectorsFollicum Ab Dec 2012 - May 2017Follicum AB is a listed company. The company develops new pharmaceutical treatments aiming to help people that suffer from hair growth disorders. The molecules originate from an invention based on molecules that stimulate regrowth of hair helping people that suffer from hair loss (alopecia).
-
Advisor To The European Commission On Risk FinancingEuropean Commission Oct 2013 - Dec 2015Brussels, BeAdvisor to the European Commission on Horizon2020 'Access to Risk Finance' -
Member Of The Board Of DirectorsPrecisense A/S 2007 - Dec 2014DkPrecisense A/S was active in the field of semi-invasive glucose monitoring by way of a subcutaneous passive sensor. Completed a structured transaction selling of assets to Medtronic Inc. April 2009. -
Member Of The Board Of DirectorsSantaris Pharma Jan 2010 - Sep 2014Santaris Pharma (now Roche Innovation Centre) developed drugs for the treatment of cancer, infectious and metabolic diseases utilizing the proprietary LNA (locked nucleic acid) technology. Acted as Sellers Representative during negotiations with Roche. Sold to Roche September 2014 at a total of 450 MUSD.
-
Member Of The Board Of DirectorsJenavalve Technology, Inc. Jan 2010 - Aug 2014JenaValve manufactures a transcatheter aortic valve implantation (TAVI) system for implantation of heart valves. The 3-feeler element includes the ability to reposition the JenaValve™ in the aorta during the implantation procedure, thus ensuring a correct and precise subcoronary, anatomical positioning within the native valve.
-
Chairman Of The Board Of DirectorsJurag Separation A/S 2007 - Feb 2014Jurag Separation developed a highly efficacious ultrafiltration system for manufacturing of high-values drugs and extracts. Acted as representative on behalf of sellers when selling the company to an undisclosed NASDAQ:OMX C20 corporation.
-
Chairman Of The Board Of DirectorsNorventum Fund No. I A/S 2002 - 2011
-
Chairman Of The Board Of DirectorsScancell A/S 2007 - 2010Scancell A/S was a first initiative to drive immuno-oncology through the clinic.
-
Investment DirectorVækstfonden 2005 - 2007Copenhagen, Capital Region Of Denmark, Dk -
Member Of The Board Of DirectorsOption Direct Aps 2003 - 2005
-
Chairman Of The Board Of DirectorsMicroshade (Photosolar Aps) 2003 - 2005
-
Investment DirectorThe Danish Technological Insitute - Technologial Innovation 2003 - 2005
-
Chairman Of The Board Of DirectorsPco Microscreening Aps 2002 - 2005
-
Chairman Of The Board Of DirectorsTopspin Aps 2002 - 2004
-
Chief Technical Director (Cto)Brisense Innovation Aps 2001 - 2003
-
Chief Operating OfficerVicim B.V. 2001 - 2003
-
ManagerRadiometer Medical A/S 1999 - 2002Brønshøj, DkManager of the R&D section and sensor technology development -
Assoc. ProfessorKøbenhavns Universitet Jan 1997 - Dec 1999København K, DkPostdoc in multivariate statistics
Claus Andersson Skills
Venture Capital
Start Ups
Biotechnology
Lifesciences
Life Sciences
Mergers And Acquisitions
Strategy
R&d
Drug Development
Commercialization
Business Strategy
Medical Devices
Pharmaceutical Industry
Entrepreneurship
Management
Technology Transfer
Investments
Biopharmaceuticals
Business Development
Ipo
Strategic Planning
Venture Financing
Executive Management
Multivariate Statistics
Board Of Directors
Financing
Life Science Industry
Biotech
Initial Public Offerings Ipo
Mergers And Acquisitions
Venture Investment
Interpersonal Skills
Valuation
Self Confidence
Deal Execution
Claus Andersson Education Details
-
Københavns Universitet - University Of CopenhagenMultivariate Statistics - Chemometrics -
Dtu - Technical University Of DenmarkChemical Engineering
Frequently Asked Questions about Claus Andersson
What company does Claus Andersson work for?
Claus Andersson works for Sunstone Life Science Ventures
What is Claus Andersson's role at the current company?
Claus Andersson's current role is General Partner, PhD, Life Science Venture Capital.
What is Claus Andersson's email address?
Claus Andersson's email address is cl****@****sson.dk
What is Claus Andersson's direct phone number?
Claus Andersson's direct phone number is +45227*****
What schools did Claus Andersson attend?
Claus Andersson attended Københavns Universitet - University Of Copenhagen, Dtu - Technical University Of Denmark.
What skills is Claus Andersson known for?
Claus Andersson has skills like Venture Capital, Start Ups, Biotechnology, Lifesciences, Life Sciences, Mergers And Acquisitions, Strategy, R&d, Drug Development, Commercialization, Business Strategy, Medical Devices.
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Aero Online
Your AI prospecting assistant
Select data to include:
Total price:
$0.00
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial